Capstan Therapeutics

News

AbbVie's $2.1bn buy of Capstan lifts its immunology pipeline

AbbVie has agreed to buy Capstan for up to $2.1bn, expanding its pipeline with an in vivo CAR-T therapy for autoimmune diseases.

News

Mirador’s massive $400m first round, and other financings

If any more evidence were needed of a bounceback in venture financing for biotechs after a dip in 2023, the $400 million first round just announced by Mirador Therapeutics

News

Preparing for an influx of cell and gene therapy approvals

CapstanTx secures $165 million to deliver precise in vivo ce...

Yesterday, the biotechnology company Capstan Therapeutics launched with $165 million in seed and Series A funding for it to build on its foundational insights into precision in vivo

AbbVie's $2.1bn buy of Capstan lifts its immunology pipeline

Mirador’s massive $400m first round, and other financings

CapstanTx secures $165 million to deliver precise in vivo ce...

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Editor's Picks